title: Management of menstrual migraine: a review of current abortive and prophylactic therapies.
abstract: After menarche, women have an increased prevalence of migraine compared to men. There is significant variability in the frequency and severity of migraine throughout the menstrual cycle. Women report migraines occur more frequently during menses, and that those are more severe than other migraines. This creates a unique challenge of effectively treating menstrually related and pure menstrual migraines. As with treatment of other migraines, both abortive and prophylactic treatment regimens are used. Triptans demonstrate efficacy in the abortive management of menstrually related and pure menstrual migraines. For migraines that occur primarily during menses or that are particularly resistant to other therapies, intermittent prophylactic therapies can be used. Naproxen and estrogens have been studied for this use. More recently, triptans have been examined and have shown efficacy for intermittent prophylaxis of menstrual migraine.
authors.affiliation: Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sullivan
authors.forename: Cheryl
authors.initials: C
authors.lastname: Bushnell
mesh_terms: D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects / Q000502:physiology; D008881:Migraine Disorders / Q000150:complications* / Q000188:drug therapy* / Q000517:prevention & control; D009288:Naproxen / Q000494:pharmacology / Q000627:therapeutic use; D011293:Premenstrual Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000517:prevention & control; D014363:Tryptamines / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D014363:Tryptamines; D009288:Naproxen